Vernakalant Facilitated Electrical Cardioversion: A Randomized, Open Label Pilot Study Comparing Intravenous Vernakalant and Amiodarone for Drug-Enhanced Electrical Cardioversion of Cardioversion-Resistant Atrial Fibrillation

Trial Profile

Vernakalant Facilitated Electrical Cardioversion: A Randomized, Open Label Pilot Study Comparing Intravenous Vernakalant and Amiodarone for Drug-Enhanced Electrical Cardioversion of Cardioversion-Resistant Atrial Fibrillation

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2013

At a glance

  • Drugs Vernakalant (Primary) ; Amiodarone
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2013 New trial record
    • 09 Mar 2013 Primary endpoint 'Conversion-to-sinus-rhythm' has been met.
    • 09 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top